Skip to main content
Top
Published in: Clinical Rheumatology 10/2007

01-10-2007 | Case Report

Churg–Strauss syndrome associated with leukotriene receptor antagonists (LTRA)

Authors: R. Cuchacovich, M. Justiniano, L. R. Espinoza

Published in: Clinical Rheumatology | Issue 10/2007

Login to get access

Abstract

Churg–Strauss syndrome (CSS) is a rare vasculitic disorder that generally occurs in patients with bronchial asthma. CSS is being increasingly recognized in asthmatic patients treated with leukotriene receptor antagonists. However, the nature of this relationship remains to be elucidated. The present report describes three asthmatic patients who developed clinical manifestations highly suggestive of CSS, although one patient lacked the presence of eosinophilia. The patient, however, exhibited biopsy-proven cutaneous necrotizing vasculitis, which improved after withdrawal of montelukast. The second patient presented with systemic constitutional signs including fever, malaise, arthralgias, clinical jaundice, peripheral blood eosinophilia, and biopsy-proven eosinophilic hepatitis. The third patient also had circulating eosinophilia, scleritis, and arthritis. All patients improved after discontinuation of the leukotriene receptor antagonist (montelukast).
Literature
2.
go back to reference Wechsler ME, Garpestad E, Flier SR et al (1998) Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 279:455–457PubMedCrossRef Wechsler ME, Garpestad E, Flier SR et al (1998) Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 279:455–457PubMedCrossRef
3.
go back to reference Wechsler ME, Finn D, Gunawardena D et al (2000) Churg–Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 117:708–713PubMedCrossRef Wechsler ME, Finn D, Gunawardena D et al (2000) Churg–Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 117:708–713PubMedCrossRef
4.
go back to reference Conen D, Leuppi J, Bubendorf L et al (2004) Montelukast and Churg–Strauss syndrome. Swiss Med Wkly 134:377–380PubMed Conen D, Leuppi J, Bubendorf L et al (2004) Montelukast and Churg–Strauss syndrome. Swiss Med Wkly 134:377–380PubMed
5.
go back to reference Weller PF, Plaut M, Taggart V, Trontell A (2001) The relationship of asthma therapy and Churg–Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 108:175–183PubMedCrossRef Weller PF, Plaut M, Taggart V, Trontell A (2001) The relationship of asthma therapy and Churg–Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 108:175–183PubMedCrossRef
6.
go back to reference DuMouchel W, Smith ET, Beasley R et al (2004) Association of asthma therapy and Churg–Strauss syndrome : an analysis of postmarketing surveillance data. Clin Ther 26:1092–1104PubMedCrossRef DuMouchel W, Smith ET, Beasley R et al (2004) Association of asthma therapy and Churg–Strauss syndrome : an analysis of postmarketing surveillance data. Clin Ther 26:1092–1104PubMedCrossRef
7.
go back to reference Shimbo J, Onodera O, Tanaka K, Tsuji S (2005) Churg–Strauss syndrome and the leukotriene receptor antagonist pranlukast. Clin Rheumatol 24:661–662PubMedCrossRef Shimbo J, Onodera O, Tanaka K, Tsuji S (2005) Churg–Strauss syndrome and the leukotriene receptor antagonist pranlukast. Clin Rheumatol 24:661–662PubMedCrossRef
8.
9.
go back to reference Otani Y, Ansai S, Shibuya H et al (2003) Churg–Strauss syndrome (CSS) manifested as necrosis of fingers and toes and liver infarction. J Dermatol 30:810–815PubMed Otani Y, Ansai S, Shibuya H et al (2003) Churg–Strauss syndrome (CSS) manifested as necrosis of fingers and toes and liver infarction. J Dermatol 30:810–815PubMed
10.
go back to reference Androudi S, Iaccheri B, Brazitikos P, Papadaki T, Foster CS (2004) Bilateral chronic anterior uveitis and neuro-ophthalmologic manifestations in a patient with Churg–Strauss syndrome: an unusual ocular manifestation. Ocul Immunol Inflamm 12:59–63PubMedCrossRef Androudi S, Iaccheri B, Brazitikos P, Papadaki T, Foster CS (2004) Bilateral chronic anterior uveitis and neuro-ophthalmologic manifestations in a patient with Churg–Strauss syndrome: an unusual ocular manifestation. Ocul Immunol Inflamm 12:59–63PubMedCrossRef
11.
go back to reference Garcia-Marcos L, Schuster A (2001) Antileukotrienes in asthma: present situation. Expert Opin Pharmacother 2:441–466PubMedCrossRef Garcia-Marcos L, Schuster A (2001) Antileukotrienes in asthma: present situation. Expert Opin Pharmacother 2:441–466PubMedCrossRef
12.
go back to reference Merck (1999) Post marketing research data. Merck, Rahway, NJ Merck (1999) Post marketing research data. Merck, Rahway, NJ
13.
go back to reference Wechsler ME, Finn D, Gunawardena D et al (2000) Churg–Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 117:1–9CrossRef Wechsler ME, Finn D, Gunawardena D et al (2000) Churg–Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 117:1–9CrossRef
14.
go back to reference Guilpain P, Viallard JF, Lagarde P et al (2002) Churg–Strauss syndrome in two patients receiving montelukast. Rheumatology 41:535–539PubMedCrossRef Guilpain P, Viallard JF, Lagarde P et al (2002) Churg–Strauss syndrome in two patients receiving montelukast. Rheumatology 41:535–539PubMedCrossRef
15.
go back to reference Hellmich B, Csernok E, Gross W (2005) Proinflammatory cytokines and autoimmunity in Churg–Strauss syndrome. Ann N Y Acad Sci 1051:121–131PubMedCrossRef Hellmich B, Csernok E, Gross W (2005) Proinflammatory cytokines and autoimmunity in Churg–Strauss syndrome. Ann N Y Acad Sci 1051:121–131PubMedCrossRef
16.
go back to reference Hauser T, Mahr AD, Metzler C et al (2006) Leukotriene receptor antagonists (Montelukast) and the risk of Churg–Strauss syndrome (abstract). Arthritis Rheum 54:S496 Hauser T, Mahr AD, Metzler C et al (2006) Leukotriene receptor antagonists (Montelukast) and the risk of Churg–Strauss syndrome (abstract). Arthritis Rheum 54:S496
Metadata
Title
Churg–Strauss syndrome associated with leukotriene receptor antagonists (LTRA)
Authors
R. Cuchacovich
M. Justiniano
L. R. Espinoza
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 10/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0510-0

Other articles of this Issue 10/2007

Clinical Rheumatology 10/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.